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“A STUDY OF IMPACT OF ADMISSION MEAN PLATELET ON THE 
EFFICACY OF THROMBOLYSIS IN ST ELEVATION MYOCARDIAL 
INFARCTION” 
ABSTRACT: 
BACKGROUND AND AIMS: 
 The role of platelets in pathogenesis of myocardial infarction is well 
established. Larger metabolically and enzymatically platelets are released during 
atherosclerotic plaque rupture. Reactivity and size of the platelets are measured 
by mean platelet volume and it can be related to the burden of thrombus measured 
by post thrombolysis TIMI flow. 
METHODS: 
 Data from Institute of internal medicine and Department of cardiology, 
Madras medical college, Rajiv Gandhi Government General Hospital were 
analysed by measuring mean platelet volume on presentation and its relation to 
post thrombolysis TIMI flow. Patients were divided into two groups having mean 
platelet volume 9.5 as target. Evaluated by Pearson chi square test. 
RESULTS: 
 In our study out of 40 patients most of the patients were in the age group 
of 41-60 years(27 patients) and  in sex distribution males were in large number 
(27 patients).Significant correlation obtained between mean platelet volume and 
infarct size, TIMI flow ,platelet count ,left ventricular systolic function, number 
of vessels involved. 
CONCLUSIONS: 
 Successfulness of thrombolysis was inversely proportional to admission 
mean platelet volume. Infarct related artery patency and TIMI flow were 
inversely proportional to admission mean platelet volume. Platelet count was 
inversely proportional to admission MPV. Total count has correlated with infarct 
size. 
Key words: Myocardial infarction, TIMI flow, mean platelet volume 
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INTRODUCTION 
 
Myocardial infarction continues to major health problem both in 
industrialized world and in developing countries, even after advances in 
diagnosis and management. Mortality from STEMI has declined steadily. 
Decrease in mortality is attributed to fall in incidence of STEMI and fall in the 
case fatality rate. Nearly 10% of myocardial infarcts occur in people under age 
40, and 45%occur in people under age 65. Blacks and whites are equally 
affected. Throughout life, men are at significantly greater risk than women. 
Management of STEMI has progressed through various phases. In the 
first half of 20th century was “CLINICAL OBSERVATION PHASE” in which 
detailed recording of physical and laboratory findings with little active 
treatment for the infarction. 
In mid 1960s coronary care unit phase begins and detailed analysis of 
cardiac arrhythmias. After the introduction of pulmonary artery floatation 
catheters the stage of high technology phase started. The modern reperfusion 
era was occupied by intracoronary and intravenous fibrinolysis. 
The dominant cause of the IHD syndromes is insufficient coronary 
perfusion relative to myocardial demand, due to chronic, progressive 
atherosclerotic narrowing of the epicardial coronary arteries, and variable 
degrees of superimposed acute plaque change, thrombosis, and vasospasm. 
The role of platelets in thrombus formation is already well studied. At 
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the time of myocardial infarction, new large sized platelets are released from 
the bone marrow. The large sized platelets show high mean platelet volume. 
Hence the admission MPV has been shown to be a strong and independent 
predictor of impaired angiographic reperfusion in acute ST-segment elevation 
myocardial infarction. Reestablishment of IRA flow is associated with 
decreased mortality in patients with acute myocardial infarction. It may be 
speculated that failure to restore epicardial coronary blood flow after 
thrombolytic administration could contribute at least in part to higher 
morbidity and mortality rates in patients with an elevated MPV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
AIMS AND OBJECTIVES 
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AIMS & OBJECTIVES 
 
 To study about the impact of admission mean platelet volume on the 
efficacy of thrombolysis in ST elevation myocardial infarction. 
 
 To study about the impact of admission mean platelet volume and 
successfulness of thrombolysis, left ventricular function and coronary 
patency after thrombolytic therapy in ST elevation myocardial 
infarction 
 
 
 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
 
MYOCARDIAL INFARCTION: 
Defined pathologically by myocardial cell death by prolonged 
ischemia. Clinical diagnosis requires integrated biochemical, 
electrocardiographic and imaging .1 
Classification of Myocardial infarction:1,2 
TYPE FEATURES 
  1 Spontaneous due to plaque rupture, erosion, fissuring or dissection 
  2 Demand supply mismatch (anemia, hypotension, hypertension, 
coronary spasm, coronary embolism) 
  3 Sudden unexpected cardiac death(new ST elevation, new LBBB, 
Angiography evidence) 
  4a PCI associated  
  4b Stent thrombosis 
  5 CABG associated 
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Pathophysiology:3,4 
Types of abnormal contraction patterns: 
 Hypokinesia. 
 Akinesia 
 Dyssynchrony 
 Dyskinesia. 
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Ischemia at distance:5 
                 Collaterals loss due to infarct artery 
 
 Contractile dysfunction in non-infarcted zone 
 
HEART MUSCLE: 
Gross pathology:6 
Difficult to identify within 6 hours. 
1) Transmural infarction 
2) Non transmural (Sub-endocardial infarction) 
Transmural infarction: 
Occlusion of coronary artery 
 
 
Full thickness myocardial necrosis 
Single coronary artery localization 
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Nontransmural myocardialinfarction :   
Severely narrowed but patent coronary arteries 
 
 
Nontransmural patchy infarction 
HISTOLOGIC AND ULTRASTRUCTURAL CHANGES:7,8,9 
TIME GROSS LIGHT MICROSCOPY ELECTRON 
MICROSCOPY 
TTC 
DEFECT 
0-3hrs  Waviness of border 
cardiac  fibres  
Depletion of 
glycogen, 
myofibrillar 
relaxation, 
swelling of 
mitochondria 
Present 
3-12hrs  Coagulation necrosis, 
infiltrate of neutrophils, 
edema 
Disruption of 
sarcolemma, 
amorphous 
densities in 
mitochondria 
Present 
12-24 hrs Pallor 
 
 
Coagulation necrosis plus 
contraction bands 
 Present 
 
 
 
1 day –  
10 days 
 
Pallor 
plus 
periphery 
hyperemia      
 
Myofibre disintegration, 
macrophage phagocytosis 
 Present 
10 – 
6 weeks 
Soft and 
yellow 
Phagocytosis completed, 
neovascularised 
granulation tissue 
 Present 
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TTC (triphenyltetrazoliumchloride) staining3 
 Intact, non infarcted myocardium + active LDH  brick red colour 
 Infarcted myocardium + inactive LDH  unstained pale zone 
 
  
9 
 
COAGULATION NECROSIS: 
Central region persistent ischemia leads to muscle cells arrest in 
relaxed state with mitochondrial densities. 
 
CONTRACTION BANDS/COAGULATIVE MYOCYTOLYSIS:10 
Reflow following severe ischemia leads to calcium influx into 
periphery of infarcts leads to arrest of cells in the contracted state. 
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MODIFICATION OF PATHOLOGIC CHANGES BY 
REPERFUSION:11 
Early reperfusion <20 minutes—Prevents necrosis 
Area of necrosis is directly related to total coronary artery occlusion 
time, oxygen consumed by myocardium, collateral blood flow. 
Reperfusion of infarcted myocardium produces early and exaggerated 
peaking of CK-MB, and Troponin I & T due to accelerated wash out of 
intracellular protein. 
RIGHT VENTRICULAR INFARCTION:12 
• Occurs in 50% of patients with inferior wall infarction. 
• Isolated RVMI 3—5% of autopsy proven cases 
• Long ischemic periods sustainability and excellent contractile 
function recovery. 
11 
 
 
ATRIAL INFARCTION:13 
           10% of cases 
           Most common site—Right atrial appendage 
Frequent atrial arrhythmias. 
COLLATERAL CIRCULATION:14 
Collateral circulation well developed in following conditions 
>75% stenosis in one or more arteries 
Severe anemia, COPD, cyanotic congenital heart disease 
Hypertrophy of left ventricle 
Collaterals flow is inversely proportional to infarct size and aneurysm. 
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PATHOPHYSIOLOGY: 
LEFT VENTRICULAR FUNCTION:15 
Sufficient ischemic injury 
 
Left ventricular pump failure 
 
Decreased cardiac output, decreased stroke volume, decreased blood 
pressure, increased end systolic volume 
 
Hemodynamic predictor of mortality is rise in end systolic volume. 
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Circulatory mechanism in MI16 
 
 
  
14 
 
REMODELLING17:  
Changes in size, shape, thickness of infarcted and noninfarcted 
segments. 
Infarction of myocardium 
 
Hypokinesia or akinesia 
 
Sympathetic system activity 
Frank-Starling mechanism 
 
Dyskinesia of noninfarcted region 
Paradoxical systolic bulging 
 
Thinning and elongation of infarct segment 
Abnormal contracting segment>15%--Ejection fraction decreases18 
Abnormal contracting segment>25%--Clinical heart failure 
Abnormal contracting segment>40%--Cardiogenic shock 
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INFARCT EXPANSION19: 
              Dilation and thinning which is acute otherwise not explained by 
additional myocardial necrosis. 
Determinants19: 
1. Muscle bundle slippage 
2. Myocardial cell disruption 
3. Necrotic zone tissue loss 
Preinfarction wall thickness inversely proportional to infarct thinning. 
• Apex –Thinnest region highly vulnerable to remodeling. 
ECHO : Non contractile region elongation 
EFFECTS OF TREATMENT: 
20
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20Inhibitors of RAAS - Decreases remodeling 
Angiotensin II blockade - Dysfunction of endothelium attenuated. 
                                              Antiatherogenesis 
Aldosterone blockade - Decrease in collagen deposition 
                                            Decrease in ventricular arrhythmias 
CLINICAL FEATURES: 
General appearence21 
 Anxious 
 Restless 
 LEVINE SIGN –Clenched fist held against chest 
 Skin pallor and cold perspiration—Sympathetic stimulation and left 
ventricular failure. 
 Pink, frothy, blood stained sputum-Pulmonary edema 
 Cold clammy skin, cyanosis, shock-cardiogenic shock. 
Circardin periodicity:22,23 
Early morning hours 
 
Increased catecholamines,cortisol 
Increased platelet aggregability 
 
Peak hours 6am –NOON 
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Periodicity was absent in patients receiving β blocker and aspirin 
Nature of the pain:24 

 Duration – 30minutes to hours 
 Character – Compressing,choking,oppressing,sensation of heavy 
weight, squeezing 
 Site – Retrosternal, substernal 
 Radiation—Left shoulder, left ulnar aspect of arm,wrist and little 
finger, also radiates to neck, jaw, interscapular region 
Pain produced by injured or ischemic myocardium not from necrotic tissue. 
Associated symptoms24: 
 Vagal reflex or Bezold –Jarisch reflex 
Nausea, vomiting 
 Breathlessness 
 Palpitation 
 Sense of impending doom 
 Cold perspiration 
 Silent MI—Diabetes mellitus, Hypertension 
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PHYSICAL EXAMINATION:25 
Heart rate: 
                   Bradycardia –Inferior or right ventricular MI 
                  Tachycardia –Anterior wall MI 
Blood pressure:26 
Normotension –Non complicated MI 
Hypertension –Early hours due to adrenergic discharge 
Hypotension   Inferior wall MI (Parasympathetic  
  Opioid         stimulation) 
  Cardiogenic shock  
Temperature: 
             Begin to rise within 4 to 8 hours 
            Rectal temperature –38.3°c to 38.9°c 
            Temperature normalizes within 4—5 days 
Respiration:27 
              Rate –Slight elevation and settles with treatment 
>40/min –Pulmonary edema 
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             Character –Cheyne-Stokes in cardiogenic shock, elderly, heart 
failure, opioid  
Jugular venous pulse:26 
Most of the patients not elevated 
Prominent ‘a’ wave – LV failure induced pulmonary hypertension 
Tall ‘cv’ wave – right ventricular papillary muscle ischemia induced 
tricuspid regurgitation 
Carotid pulse: 
Pulsus alternans – severe left ventricular dysfunction 
Small pulse – reduced stroke volume 
Sharp, brief upstroke – left to right shunt due to ventricular septal 
rupture or mitral regurgitation 
CHEST EXAMINATION: 
Killip and Kimball classification 28,31 
• Class I – no rales, no S3 
• Class II – rales <50% lung fields, +/- S3 
• Class III – rales >50% lung fields, and pulmonary edema 
• Class IV – cardiogenic shock 
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CARDIAC EXAMINATION:29,30 
Palpation: 
Presystolic pulsation – left atrial vigorous contraction against non-
compliant ventricle. 
An outward movement of the left ventricle in early diastole coinciding 
with S3 represents systolic dysfunction of left ventricle. 
Heart sounds: 
• S1 – soft and muffled represents prolonged PR interval 
• Paradoxical splitting of S2 – left bundle branch block 
• S3  
o severe LV dysfunction due to elevated filling pressures 
o Can also occur in mitral regurgitation and ventricular septal 
rupture 
• S4 almost universally present in STEMI patients in sinus rhythm 
and has no prognostic value 
Murmurs: 
• Mitral valve apparatus dysfunction (papillary muscle dysfunction or 
dilatation of LV) – produces transient systolic murmur 
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• Papillary muscle rupture – apical holosystolic murmur with thrill 
• Ventricular septal rupture – holosystolic murmur with thrill along left 
sternal border 
• Right ventricular failure causing tricuspid regurgitation – systolic 
murmur along left sternal border with positive Carvallo’s sign 
• Friction rub – heard within one day or as late as two weeks, most 
common on second or third day. Highly evanescent finding.  
• Dressler’s syndrome – late onset pericarditis (even after 3 months) 
LABORATORY FINDINGS:32,33,34 
Serum markers of myocardial damage: 
Necrosis of myocardium  sarcolemmal membrane disruption  diffusion 
of intracellular macromolecules in to the cardiac interstitium  further 
diffusion in to micro vasculature and lymphatics. 
PAPP released in to the blood during the stage of plague vulnerability. 
After plaque rupture IMA is released during the initial period of ischemia.  
22 
 
 
Creatine kinase isoenzymes: 
3 isoenzymes  
1. MM – skeletal muscle 
2. BB – brain and kidney 
3. MB – heart (small quantity is seen in small intestine, diaphragm, 
prostate, tongue, uterus) 
Relative index of CK-MB: 
CK MB MASS
CK ACTIVITY  > 2.5  cardiac origin 
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False positive results can occur in myocarditis, cardiac catheterization, 
shock, cardiac surgery, trauma and skeletal muscle injury.  
Cardiac specific troponins: 
Troponin complex 
• Troponin C – binds to calcium 
• Troponin I – binds to actin and inhibits actin-myosin interaction, 2-3% 
in cytosol 
• Troponin T – binds to tropomyosin, 6% in cytosol 
Cut off value – Value exceeding 99% of the reference control group 
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Biomarkers for Evaluation of Patients with ST-Segment Elevation 
Myocardial Infarction32,33,34 
 
Classification of Different Types of Myocardial Infarction: Suggested 
Grid for Reporting Results 
MULTIPL
ES X 99% 
MI Type 
TOTA
L NO. 1 (SPONTANEO
US) 
2 
(SECONDA
RY) 
3(SUDD
EN 
DEATH) 
4 
(PC
I) 
5(CAB
G) 
1-2x             
2-3x             
3-5x             
5-10x             
>10x             
Total no.             
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OTHER TESTS: 
Lipid profile:  
Total cholesterol and HDL remain at baseline during the initial 24-48 
hours, after that both values begin to fall HDL > Total cholesterol 
In patients admitted after 48 hours, measurement of serum lipids is 
advised after 8 weeks. 
Hemostatic markers: 
Leukocytes – elevated according to the level of necrotic process, 
directly proportional to in-hospital mortality, count ranges from 12,000 – 
20,000, correlates with the angiographic appearance and clinical outcomes. 
Blood viscosity – elevated due to hemoconcentration, elevated levels 
of alpha 2 globulin and fibrinogen 
ESR – elevated due to increased level of fibrinogen not related to level 
of necrotic process 
Hemoglobin – J shaped relationship with the clinical events, levels 
<14 leads to decreased oxygen supply, levels >17 leads to polycythemia and 
increase in blood viscosity 
CRP – elevated and correlates with the infarct related artery and heart failure 
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Platelets – metabolically and enzymatically active platelets are 
released. They are large sized and contains increased granules, increased 
levels of thromboxane, beta thromboglobulin, P-selectin, GP IIb/IIIa receptor 
and fibrinogen. Platelet factor 4, thrombin, antithrombin complex and 
fibrinopeptide A are increased and correlates with mortality 
Large sized platelets 
Increased aggregation to ADP 
Increased thrombus burden 
Balance between thrombolysis and thrombogenesis tilted towards thrombogenesis 
  Leads to failed thrombolysis 
Mean platelet volume: 
Large sized reactive platelets are measured by mean platelet volume 
Instrument used : Beckman – Coulter LH780 Hematology analyser 
Normal MPV: 7.5 – 11.5 fL 
In acute MI – MPV has significant correlation with the prognosis 
Platelet count – at the initial hours of MI, platelet counts may be decreased 
due to consumption which correlates with the prognosis. 
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ELECTROCARDIOGRAM:35 
In 1887 Waller directly recorded cardiac electrical potentials. 
In 1901 Einthoven registered electrical activity by string galvanometer. 
 
Principle:36 
Ionic fluxes across cell membrane and cells produce transmembrane 
ionic currents which are synchronized by activation and recovery of cardiac 
cells generating electrical field in and around the heart 
 
ESC STEMI DIAGNOSTIC CRITERIA: 
SEX ST ELEVATION LEADS 
MALE 
<40 years 
>40 years 
 
≥0.25 mV 
≥0.2 Mv 
 
atleast 2 contiguous leads 
 
FEMALE ≥0.15 mV 
≥0.1 mV 
V2, V3 
Other leads 
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POSITIONING OF LEADS:37 
 
ECG IN MI: 
Important diagnostic tool for  
               1.Duration 
               2.Extent 
               3. Topography 
              4.Any other abnormalities. 
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MECHANISM OF ST ELEVATION:38 
 
 
DIASTOLIC CURRENT OF INJURY HYPOTHESIS: 
Resting mebrane potential of ischemic cells lowered and in a 
depolarized state where as non ischemic cells remain in repolarized state. 
During diastole current flows from depolarized to repolarized segments and 
hence directed away from negative zone producing TQ segment depression. 
30 
 
As the ECG recorders use AC coupled amplifiers there will be 
electronic compensation for TQ segment depression as ST segment elevation 
an apparent shift. 
 
SYSTOLIC CURRENT HYPOTHESIS: 
1.Early pathologic repolarization 
2.Decreased amplitude of action potential 
3.Action potential upstroke velocity is decreased. 
 
Establishment of voltage gradient between normal and ischemic zone 
 
ST SEGMENT ELEVATION 
 
  
TOPOGRAPHICAL LOCALISATION:
 
LOCALISATION OF INFERIOR WALL MI
31 
39 
:40 
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ECHOCARDIOGRAPHY:41 
Uses: 
To diagnose or exclude MI in case of non diagnostic ECG 
Estimation of myocardium at risk and infarct size 
Identification of complications 
Risk stratification 
Assesment of reperfused segments 
 
Principle:42 
Lines or shapes produced by reflection of ultrasound beams by 
cardiovascular structures. 
Can be taken in one, two,three dimensional mode. 
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ASE RECOMMENDATIONS:43 
17 Segment model has been used for regional wall motion analysis. 
 
GRADING OF CONTRACTILE FUNCTION:44 
 GRADE1: Normal >40% thickening with systole 
 GRADE2: Hypokinesis(10 to 40%thickening) 
 GRADE3:Akinesis <10% thickening 
 GRADE4:Dyskinesis 
 GRADE5:Aneurysm 
 
WALL MOTION SCORE INDEX45 =  
     / 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DETECTION OF MECHANICAL COMPLICATIONS: 
VENTRICULAR SEPTAL RUPTURE:46 
Almost always in thinned dyskinetic myocardium 
Inferoseptal rupture signifies right ventricular involvement carries a 
poor prognosis. 
Identified by right to left shunt. 
 
ACUTE MR:47 
Causes: 
1.Papillary muscle dysfunction 
2.Global or regional LV remodeling 
3.Papillary muscle rupture - Posteromedial (supplied by single  
coronary artery) 
4.Systolic anterior motion of mitral valve 
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LEFT VENTRICULAR ANEURYSM:48 
Most common site—Apex >Inferobasal area 
Contains all layers of myocardium 
Systolic thinning and bulging is common. 
 
THROMBUS: 
Non homogenous density 
Underlies akinetic or dyskinetic wall 
Margins are distinct 
Contrast echo needed for confirmation 
 
 MORTALITY PREDICTING SCORE 
TREATMENT:49 
 
36 
(TIMI)51 
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ANALGESICS: 
Morphine 
 Drug of choice 
 4-8mg IV followed by 2-8mg every 15 minutes 
 Mechanism of action – peripheral arterial and venous dilatation 
 Side effects – hypotension, respiratory depression, vomiting 
ASPIRIN: 
 Loading dose – 160-325mg  
 Chewing increases buccal absorption rather than swallowing 
NITRATES: 
 Mechanism of action – coronary vasodilatation and increased venous 
capacitance 
 Contraindication – right ventricular MI, Systolic BP < 90mmHg and 
bradycardia 
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BETA-BLOCKERS:50 
Metoprolol 5mg IV bolus 
   
Hemodynamically stable                                         hemodynamically unstable 
                                                              SBP<100 mm Hg 
Bolus as needed                                                             HR< 60/min 
 
Oral 50mg 6th hourly for 2 days                              No further dosing 
 
        100mg bd 
Contraindication: 
• Rales more than 10cm from diaphragm,  
• Systolic BP < 90 mm hg 
• Heart rate < 60/min 
• First degree AV block  
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OXYGEN: 
Only useful if SaO2 < 90% 
Mode of administration: 2-4 lit/min 100% O2 by oxygen mask or nasal 
prongs for 6-12 hours 
Oxygen 
 
Increases Systemic vascular resistance & arterial pressure 
 
Decreases cardiac output 
FIBRINOLYTIC THERAPY:53 
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APPROACH TO STEMI PATIENT 
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FIBRINOLYTIC THERAPY: 
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ANTICOAGULANTS:54 
UNFRACTIONATED HEPARIN: 
• Used for atleast 48 hours 
• Loading dose 60U/kg bolus, followed 12U/kg/hr infusion for 48 hours 
• Target aPTT – 1.5 to 2 times the control  
• Adverse effects 
o bleeding,  
o heparin induced thrombocytopenia (HIT) – common in females, 
elderly age 
LOW MOLECULAR WEIGHT HEPARIN:54 
Enoxaparin: 
• Age <75  30mg IV bolus followed by 1mg/kg bd subcutaneously 
• Age >75  No IV bolus, followed by 0.75mg/kg bd subcutaneously 
• Creatinine clearance <30ml/min -  30mg IV bolus, followed by 1mg/kg 
OD subcutaneously 
• Advantages – reocclusion, reinfarction, recurrence rates decreased, 
high bioavailability, decreased incidence of HIT  
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Hirudin &Bivalirudin:55 
• Recurrence of MI reduced by 25-35%  
• No mortality reduction 
• Adverse effect – stent thrombosis 
FACTOR ‘X’ A ANTAGONISTS: 
Fondaparinux:56 
• 2.5mg subcutaneous – not superior to unfractionated heparin 
• Catheter thrombosis when used alone, without another antithrombin 
agent 
 
ANTIPLATELETS:57 
Thrombi rich platelets are resistant to fibrinolysis. Hence single 
antiplatelet agent is not efficient. 
Although aspirin inhibits cyclooxygenase pathway, platelet activation 
continues to occur by thromboxane A2 independent pathways.  
P2Y12 inhibitors can be used to prevent platelet aggregation 
Clopidogrel – loading dose 300-600mg, maintenance dose 75mg/day 
Ticlopidine – loading dose 500mg, maintenance dose 250mg BD 
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Prasugrel – reduces stent thrombosis 42% compared with clopidogrel 
Reversible P2Y12 inhibitor – ticagrelor loading dose 180mg, 
maintenance dose 90mg BD 
 
ATHEROSCLEROSIS:58 
It’s a chronic inflammatory process 
Common sites: 
1. CORNARY ARTERIES 
2. BIFURCATION OF CAROTID ARTERIES 
3. ABDOMINAL AORTA 
4. PROFUNDA FEMORIS 
RESPONSE TO INJURY HYPOTHESIS: 
Endothelial dysfunction is the initiating event that predisposes to 
atherosclerosis. 
 
ENDOTHELIAL DYSFUNCTION:60 
Encompasses derangement in any of the following components 
1.Vascular tone 
2. Inflammation 
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3.Growth 
4.Preservation of fluidity of blood 
VASCULAR TONE:60 
Normal vascular tone is maintained by nitric oxide 
 
Mechanism of vascular tone derangement 
Modified LDL   High cholesterol 
 
Nitric oxide synthesis derangements                      Oxygen free radical 
 
Decreased NO production                NO inactivation 
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ENDOTHELIAL INFLAMMATION61 
Invasion of  oxidized lipoproteins 
 
Expression of adhesion molecules62 
 
selectin trap monocytes                                       VCAM and ICAM establish firm  
and leukocytes                                                         attachment to endothelium  
 
        Expression of MCP—1 63                               Expression of M—CSF 
        Diapedesis                                                    Monocyte to macrophage         
                                                                                     Transformation 
 
ABNORMAL CONTROL OF VASCULAR GROWTH:64 
Normal endothelium inhibits smooth muscle proliferation 
Correct pathogenetic mechanism is unknown 
Growth factors like MCP—1 and M-CSF may be responsible for 
proliferation of smooth muscle 
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Inflammation induced NO bioactivity decrease also involved in smooth 
muscle proliferation. 
Stability of plaque is given by smooth muscle proliferation 
Shoulder region apoptosis of smooth muscle leads to unstable 
vulnerable plaque. 
 
ABNORMAL CONTROL OF BLOOD FLUIDITY:66 
Imbalance between factors inhibiting and favouring thrombosis leads 
to prothrombotic state and thrombosis 
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AHA ATHEROSCLEROTIC PLAQUE CLASSIFICATION67 
 
 
 
 
 
 
 
 VULNERABLE PATIENT:
Combination of vulnerab
Vulnerable plaque:69 
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le plaque, blood and myocardium 
 
 
 Markers of blood vulnerability
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THROMBOPOIESIS:72 
1×1011 produced every day 
Single megakaryocyte produces 1000—3000 platelets 
Half life of platelet—10 days 
Platelet count is inversely proportional to thrombopoietin levels 
 
Origin of platelets from megakaryocytes 
 The megakaryocyte is a large hematopoietic cell, the cytoplasm of 
which fragments to form circulating blood platelets. The histogenesis of 
platelets from megakaryocytes was first described by James Wright in 1910. 
The megakaryocytes are sessile polyploid cells which in turn descend from 
diploid pluripotent hematopoietic stem cells of marrow.73 The 
megakaryocytes are imprisoned within the sub endothelial layer of marrow 
sinuses by their very girth and volume (average 5000 femto litres, Zhang YJ, 
1991). In these marrow niches,    mononuclear progenitors undergo diploid 
doublings by the unique process of endomitosis.   Subsequently   the   
polyploidy megakaryocytes accumulate a bulky compartmentalized 
cytoplasmic mass with large volumes that at end stage maturation 
disintegrates abruptly to yield between 1000 and 8000 platelets having a 
volume of 7-9 femto litres each (Martin et al, 1982; Stenberg and Levin, 
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1989;Corash, 1989). Megakaryocytes are suicidal micro organs whose 
mission is to  proliferate and then fragment their cytoplasm on  demand to  
maintain blood  platelets  at  relatively steady  levels of about 1,50,000-
3,50,000/mm3. 
 Maintenance of platelet counts within this range represents a surplus of 
over 10 times that is   necessary to ensure routine haemostasis but provides a 
precautionary reserve for times of excess platelet loss or consumption 
 
Mechanism of formation: 
Megakaryocyte 
 
Fragmentation of membranes 
 
Proplatelets 
ELECTRON MICROSCOPY:75 
 Glycocalyx composed of glycoproteins, glycolipids, and 
mucopolysaacharides. Platelets contains sialic acid which contributes to 
negative charge and prevents adhering from one another and also to the 
endothelium which is also negatively charged. 
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Plasmamembrane: 
Trilaminar structure 
Outer platelet membrane—Contains receptors  for interaction 
Phospholipids               --57% of total content 
                                          Inner membrane 
                                         Phosphatidyl serine—negatively charged 
ORGANELLES: 
Peroxisomes:76 
Plasmalogen synthesis 
Platelet activating factor synthesis 
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Mitochondria:77 
4—7 in number 
Hyperglycemia 
 
Superoxide 
 
Platelet aggregation 
Lysosomes: 
Contains acid hydrolases, β glucuronidases,cathepsin,aryl sulfatase, 
collagenase 
LAMP 1,2,3—markers of platelet release reaction 
Dense bodies:78 
20—30 nm in diameter 
Highly osmophilic 
ATP:ADP—2:3 
Contains serotonin in high concentration 
Also contains calcium, magnesium 
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Alpha granules:79 
Most abundant granules 
50—80 per platelet 
200 nm in diameter 
 
 
Nucleoid: 
Eccentric accentuated electron density containing β-thromboglobulin, 
platelet factor –4 proteoglycans. 
Electron lucent areas rich in Vwf, multimerin, Factor V 
Cytoskeleton80 
General structure: The platelet cytoskeleton contains 30 to 50% of 
total platelet protein and is made up of three major structural components: an 
actin microfilament network present throughout the cytoplasm, a microtubule 
coil localized at the platelet periphery and a membrane skeleton comprising a 
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network of short actin filaments that underlies the inner surface of the plasma 
membrane. Although they are distinct structures, interconnections between 
these elements are present. 
Upon platelet activation, the proportion of filamentous actin rapidly 
increases to 60-70%. Polymerization of actin monomers at platelet 
peripheries to form filopodia. 
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LIGHT MICROSCOPY:82 
Blood films made from EDTA anticoagulation platelets appear as 
small round bluish gray particles with purple granules. 
Mean diameter—1.5--3µm 
 
 
PHYSIOLOGY OF THROMBUS FORMATION:84 
Hemostatic system is maintained in well controlled fashion. 
Exposure of normally concealed blood vessel wall by intact endothelial 
lining leads to dynamic process of platelet adhesion, activation,aggregation.  
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Atherosclerosis, plaque rupture/erosion 
 
vWF and collagen exposure 
    GbIb-IX receptor 
Adhesion 
 
Activation 
Confirmational change in  œIIβ3 
 
Receptor cross linking 
Aggregation 
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PLATELET –LEUKOCYTE INTERACTION: 
 
P selectin + PSGL-183 
 
Stimulates monocytes 
 
Release tissue factor 
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Fibrinogen + αMβ2 in leukocytes (or) αIIβ3 in platelets 
 
Binds and activates factor X 
 
Activates factor II 
 
Thrombin 
 
Fibrinogen  fibrin polymer (crosslinked fibrin clot) 
 
Coronary artery occlusion 
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CORONARY ARTERIOGRAPHY: 
 Angiography of coronary arteries is the standard diagnostic procedure 
to identify atherosclerotic disease induced anatomical changes. First 
performed in 1959 by SONES.85 
TECHNIQUE86 
PREPARATION OF THE PATIENT 
Tests to be done 
1.Baseline electrocardiogram 
2.Complete blood count 
3.Coagulation panel 
4.Renal function test 
5.Electrolytes 
Drugs to be stopped: 
Warfarin should be stopped before 2days 
 INR <2  --Transfemoral approach 
 INR<2.5 –Transradial approach 
 Patients having high risk of thromboembolism like atrial fibrillation, 
mitral valve disease,previous thromboembolism history can be treated with 
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low molecular weight heparin subcutaneously or intravenous unfractionated 
heparin. 
PCI undergoing patients should receive Aspirin 162—325mg 2 hours 
before the procedure. 
VASCULAR ACCESS88 
FEMORAL ARTERY – Most commonly used 
                                     Right and left can be used 
Site of puncture: 
Common femoral artery anterior wall 
Centimeters below inguinal ligament –To prevent retroperitoneal 
hemorrhage. 
Proximal to the bifurcation of profunda and superficial femoral artery - 
to prevent pseudoaneurysm. 
Femoral artery and vein cannulation ipsilaterally avoided to prevent 
arteriovenous fistula. 
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RADIAL APPROACH:87 
Preffered due to easy catheter entry and removal. 
Allen test –Ulnar artery patency. 
2000---5000 U Unfractionated heparin or Bivalirudin –Prevent 
thrombosis. 
Intraarterial verapamil or nitrglycerine –Prevent spasm. 
 
Advantages: 
 Low cost. 
 Better coronary visualization. 
 Less bleeding complications. 
 
CATHETERS 
Made from polyurethane or polyethelyne. 
Outer diameter size 4F –8F. 
5F OR 6F –Commonly used. 
JUDKINS OR AMPLATZ CATHETER.89 
Size determined by bodyhabitus and aortic root size 
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DRUGS DURING THE PROCEDURE: 
ANALGESICS: 
Diazepam 2.5—10mg plus Diphenhydramine 25—50mg oral 1 hour 
before the procedure (or)  
Intravenous midazolam 0.5—2mg plus fentanyl25 –50micrograms  
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ANTICOAGULANTS: 
Intravenous unfractionated heparin 2000—5000units intravenously in 
high risk patients, severe aortic stenosis. 
Heparinised saline flush –Prevents microthrombi 
Reversal of heparin 100units by 1mg protamine. 
Protamine contraindicated in previous catheterization by radial or 
femoral artery, NPH Insulin use,unstable angina, complex coronary anatomy. 
 
Periprocedural ischemia: 
Causes: 
           1.Tachycardia 
           2.Hypertension 
           3.Contrast agents 
           4.Dynamic platelet aggregation. 
           5.Coronary vasospasm. 
6. Increased vasomotor tone. 
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TREATMENT: 
1.Nitroglycerine   0.3mg sublingually or50 –200 microgram 
intracoronary or 10—25microgram/min intravenous. 
2.Intravenous metoprolol 2.5—5mg or propranolol 1—4mg. 
           3. Intraaortic balloon counterpulsation. 
 
CONTRAST AGENTS 
Principle: 
IODINE 
 
X ray absorption 
Energy range 
High - osmolar ionic agents: 
                          1.Sodium diatrizoate 
                          2. Sodium meglumine diatrizoate     
Adverse effects: 
Due to hypertonicity. 
 1.Sinus bradycardia. 
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 2.QT Prolongation. 
 3.QRS Prolongation. 
 4.ST Depression. 
 5. Ventricular fibrillation.                                                          
Non ionic low osmolar contrast agents: 
 1.Ioxaglate. 
 2.Iohexol. 
 3.Iopamidol. 
 4.Ioversol. 
 5. Iodixanol 
Side effects: 
 1.Hotflush. 
 2.Vomiting. 
 3.Hypotension—Anaphylaxis 
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Contrast induced nephropaty:90 
Risk factors: 
 1.Prior renal insufficiency. 
 2.Diabetes mellitus. 
 3.Dehydration. 
 4.Large volume of contrast material. 
Prevention: 
 1.Prior hydration. 
 2.Limited contrast usage. 
Contrast reactions grading:91 
Grade1: 
            Vomiting, nausea, vertigo—one episode. 
Grade2: 
      Hives >1 episode of fever, chills, vomiting. 
Grade3: 
              Bronchospasm, laryngospasm, hypotension, loss of consciousness, 
arrhythmia, pulmonary edema. 
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Prevention: 
 1.Prednisone 60mg(night and2 hours before procedure). 
 2.Diphenhydramine50mg. 
 3. Cimetidine 300 mg. 
 
ARTERIAL NOMENCLATURE: 
SCORING SYSTEMS:93 
1. CALIFF SCORING: 
 Coronary segments-6 
 Score-0-12 
2. CANDELL-RIERA SCORING: 
 Coronary segments-13 
 Score-0-65 
3. GENSINI SCORING: 
 Cornary segments-11 
 Score-0-72 
 
 
  
 
CORONARY ARTERY SURGERY STUDY (MODIFIED BY BYPASS 
ANGIOPLASTY REVASCULARISATION INVESTIGATORS)
                   29 segments of coronary artery are defined.
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CORONARY ARTERY DISEASE: 
Definition: 
 Obstructive coronary artery disease: >50% stenosis
 Non obstructive coronary artery disease
 Subcritical stenosis: <50% stenosis
 
LESION CHARACTERS
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:94 
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CORONARY COLLATERALS 
RENTROP CLASSIFICATION: 
 GRADE 0:No filling 
 GRADE 1: Small side branches. 
 GRADE 2:Partial epicardial filling of the coronary artery. 
 GRADE 3:Complete epicardial filling of the coronary artery. 
 
THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI) FLOW:95 
 GRADE0:No contrast flow through the stenosis. 
 GRADE1: Flows through the stenosis but no opacification 
beyond    obstruction 
 GRADE2:Slow entry in to the terminal segment or delayed 
clearance 
 GRADE3:Entry and clearance from stenosed segment similar to 
nonstenosed segment 
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TIMI FRAME COUNT: 
Number of angiographic frames till the contrast arrives distal bed of 
vessel. Coronary blood flow ml/second—{21/observed TIMI frame 
count}X1.7 
 
MYOCARDIAL NO REFLOW: 
Reduced myocardial blood flow even after opening of an epicardial 
artery 
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MATERIALS AND METHODS 
STUDY CENTRE: 
 Institute of Internal Medicine & Department of Cardiology, Madras 
Medical College and Rajiv Gandhi Government General Hospital, Chennai. 
STUDY DESIGN: 
 Observational study (Prospective and Retrospective) 
DURATION OF THE STUDY: 
 6 months 
SAMPLE SIZE: 
 40 patients 
INCLUSION CRITERIA: 
 Patients with clinical features and ST Elevation myocardial infarction 
EXCLUSION CRITERIA: 
 Patients on drugs affecting platelet count and function 
 Known coronary artery disease patients  
 Unstable angina and non ST Elevation myocardial infarction patients 
 
  
 
 
 
MATERIALS AND METHODS 
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DATA COLLECTION AND METHODS: 
 Patients admitted with ST elevation MI selected for clinical study as 
per inclusion / exclusion criteria were subjected to investigations like mean 
platelet volume, ECG, ECHO and coronary angiogram. 
 
Mean platelet volume: 
 3ml of was taken in EDTA test tube and analyzed in Beckman Coulter 
LH780 analyzer to detect the mean platelet volume; 
 Mean platelet volume is the geometric mean of the transformed log 
normal platelet volume data in impedance technology system. 
 
STASTICAL METHODS APPLIED: 
Datas were analysed using the SPSS software. Statistical significance 
was indicated by the Chi-square test. Variables were considered to be 
significant if p<0.05 
 
 
 
  
 
 
 
OBSERVATION 
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OBSERVATION AND RESULTS 
 
AGE DISTRIBUTION 
 
 
 
 
In our study, majority of the patients were in the age group of 41-60 
years. (67.5%)  
0%
10%
20%
30%
40%
50%
60%
70%
80%
<40 YRS 41-60 YRS ABOVE 60 YRS
AGE DISTRIBUTION 
<40 YRS
41-60 YRS
ABOVE 60 YRS
 Frequency Percent 
 
<40 YRS 3 7.5 
41-60 YRS 27 67.5 
ABOVE 60 
YRS 10 25.0 
Total 40 100.0 
  
 
 
 
 
Out of 40 patients, 27 patients (67.5%) were males and 13 patients 
(32.5%) were females 
 
 
 
 
32%
78 
SEX DISTRIBUTION 
 Frequency Percent 
MALE 27 67.5 
FEMALE 13 32.5 
Total 40 100.0 
68%
SEX DISTRIBUTION
 
MALE
FEMALE
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AGE GROUP & PLATELET COUNT 
 
Mean SD Minimum Maximum Range 
Platelet
_count  
<40 
YRS 
130000.00 36055.51 100000.00 170000.00 70000.00 
41-60 
YRS 
191333.33 86565.23 84000.00 330000.00 246000.0
0 
ABOVE 
60 YRS 
142500.00 72720.55 25000.00 270000.00 245000.0
0 
 
 In our study, the mean platelet count in patients <40 years was 
1,30,000, in patients 41-60 years it was 1,91,333 and in patiens >60 years it 
was 1,42,500. 
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AGE GROUP & PLATELET COUNT 
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SEX & PLATELET COUNT 
 
SEX Mean Std. Deviation Minimum Maximum Range 
platelet
_count  
MALE 170518.52 77959.74 84000.00 330000.00 246000.00 
FEMALE 182846.15 95526.48 25000.00 320000.00 295000.00 
 
SEX AND PLATELET COUNT 
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DIABETES MELLITUS & MPV 
 MPV Total 
<9.5 >9.5 
 
NORMAL 
Count 14 7 21 
% within MPV 63.6% 38.9% 52.5% 
DM 
Count 8 11 19 
% within MPV 36.4% 61.1% 47.5% 
Total 
Count 22 18 40 
% within MPV 100.0% 100.0% 100.0% 
 
Pearson Chi-square test: p value – 0.119 
 
SYSTEMIC HYPERTENSION & MPV 
 MPV Total 
<9.5 >9.5 
 
NORMAL 
Count 16 10 26 
% within 
MPV 72.7% 55.6% 65.0% 
SHT 
Count 6 8 14 
% within 
MPV 27.3% 44.4% 35.0% 
Total 
Count 22 18 40 
% within 
MPV 100.0% 100.0% 100.0% 
 
Pearson Chi-square test: p value – 0.257 
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SMOKING & MPV 
 MPV Total 
<9.5 >9.5 
SMOKING 
NORMAL 
Count 18 10 28 
% within 
MPV 81.8% 55.6% 70.0% 
YES 
Count 4 8 12 
% within 
MPV 18.2% 44.4% 30.0% 
Total 
Count 22 18 40 
% within 
MPV 100.0% 100.0% 100.0% 
 
Pearson Chi-square test: p value – 0.071 
 
ALCOHOL & MPV 
 MPV Total 
<9.5 >9.5 
Alcohol 
NO 
Count 18 10 28 
% within 
MPV 81.8% 55.6% 70.0% 
YES 
Count 4 8 12 
% within 
MPV 18.2% 44.4% 30.0% 
Total 
Count 22 18 40 
% within 
MPV 100.0% 100.0% 100.0% 
 
Pearson Chi-square test: p value – 0.071 
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DISTRIBUTION OF TYPE OF MI 
 Frequency Percent 
 
AWMI 12 30.0 
EAWMI 14 35.0 
IWMI 7 17.5 
IWMI + RVMI 3 7.5 
LWMI 3 7.5 
LWMI IWMI 1 2.5 
Total 40 100.0 
 In our study, extensive anterior wall MI was the most common MI 
present in 14 patients (35%) 
MPV IN TYPE OF MI 
 Type of MI Total 
AWMI EAWM
I 
IWMI IWMI + 
RVMI 
LW
MI 
LWMI 
IWMI 
MPV 
<9.5 
Count 11 2 6 0 3 0 22 
% 
within 
IN 
91.7% 14.3% 85.7% 0.0% 100.0% 0.0% 55.0% 
>9.5 
Count 1 12 1 3 0 1 18 
% 
within 
IN 
8.3% 85.7% 14.3% 100.0% 0.0% 100.0% 45.0% 
Total 
Count 12 14 7 3 3 1 40 
% 
within 
IN 
100.0
% 100.0% 100.0% 100.0% 
100.
0% 100.0% 
100.0
% 
 
Pearson Chi-square test: p value – 0.000 
  In our study, there was a significant correlation between 
the infarct size which was statistically significant.
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IWMI IWMI + 
RVMI
LWMI LWMI IWMI
MPV >9.5 and 
 
<9.5
>9.5
86 
 
 
 
 
PLATELET COUNT IN VARIOUS TYPES OF MI  
Platelet count 
MI 
Total AWMI EAWM
I 
IWMI IWMI + 
RVMI 
LWMI LWMI 
IWMI 
 
<1.5 
lakhs 
Count 1 10 1 3 3 1 19 
% 
within 
MI 
8.3% 71.4% 14.3% 100.0% 100.0% 100.0% 47.5% 
>1.5 
lakhs 
Count 11 4 6 0 0 0 21 
% 
within 
MI 
91.7% 28.6% 85.7% 0.0% 0.0% 0.0% 52.5% 
Total 
Count 12 14 7 3 3 1 40 
% 
within 
MI 
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
Pearson Chi-square test: p value - 0.001 
 
In our study, there was a significant correlation between low platelet 
count (<1.5 lakhs) and infarct size which was statistically significant. 
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IWMI IWMI + 
RVMI
LWMI LWMI 
IWMI
 
< 1.5 lakhs
>1.5 lakhs
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TIMI FLOW AND MPV 
 MPV Total 
<9.5 >9.5 
TIMI 
FLOW 
I 
Count 1 10 11 
% within 
MPV 4.5% 55.6% 27.5% 
II 
Count 9 7 16 
% within 
MPV 40.9% 38.9% 40.0% 
III 
Count 12 1 13 
% within 
MPV 54.5% 5.6% 32.5% 
Total 
Count 22 18 40 
% within 
MPV 100.0% 100.0% 100.0% 
 
Pearson chi-square test p value – 0.000 
In our study, there was a significant correlation between high mean 
platelet volume (>9.5) and low TIMI flow which was statistically significant 
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NUMBER OF VESSELS AND MPV 
 MPV Total 
<9.5 >9.5 
NO OF 
VESSELS 
DVD 
Count 3 12 15 
% within 
MPV 13.6% 66.7% 37.5% 
SVD 
Count 19 3 22 
% within 
MPV 86.4% 16.7% 55.0% 
TVD 
Count 0 3 3 
% within 
MPV 0.0% 16.7% 7.5% 
Total 
Count 22 18 40 
% within 
MPV 100.0% 100.0% 100.0% 
 
Pearson chi-square test p value – 0.000 
In our study, as the number of infarcted vessels increase, there was a 
significant rise in mean platelet volume (>9.5) and this was statistically 
significant. 
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TIMI FLOW & TYPE OF MI 
 
 MI Total 
AWMI EAWMI IWMI IWMI 
+ 
RVMI 
LWMI LWMI 
IWMI 
TIMI 
FLOW 
I 
Count 1 7 1 2 0 0 11 
% 
within 
MI 
8.3% 50.0% 14.3% 66.7% 0.0% 0.0% 27.5% 
II 
Count 7 6 1 1 0 1 16 
% 
within 
MI 
58.3% 42.9% 14.3% 33.3% 0.0% 100.0% 40.0% 
III 
Count 4 1 5 0 3 0 13 
% 
within 
MI 
33.3% 7.1% 71.4% 0.0% 100.0% 0.0% 32.5% 
Total 
Count 12 14 7 3 3 1 40 
% 
within 
MI 
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
 
Pearson chi-square test p value – 0.010 
As the infarct size increases there was low TIMI flow which was 
statistically significant in our study. 
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                                 TIME WINDOW& PLATELET COUNT 
 
  
TIME PLATELET Total   
<2 LAKHS >2 LAKHS   
NO % NO % NO % R P value 
 
< 3 HOURS 3 12.0% 7 46.7% 10 25.0%   
> 3 HOURS 22 88.0% 8 53.3% 30 75.0% 
-
0.388
* 
0.013 
Total 25 100.0% 15 100.0% 40 100.0%   
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CORRELATION BETWEEN TIME WINDOW& PLATELET COUNT 
 
 
 
 As the time interval to treatment increases, more platelets will be 
consumed and platelet count will be low which statistically significant in our 
study with a p value 0.013. 
 
 
 
 
96 
 
 
 
 
 
                               TYPE OF MI & TOTAL COUNT 
 
  
 TOTAL COUNT Total   
< 9000 >9000   
No. % No. % No. % Chi 
square 
P value 
MI 
TYPE 
AWMI 9 22.5% 3 7.5% 12 30.0%   
EAWMI 1 2.5% 13 32.5% 14 35.0% 18.852
* 
0.002 
LWMI 5 12.5% 2 5.0% 7 17.5%  
 
LWMI+
RWMI 1 2.5% 2 5.0% 3 7.5% 
  
LWMI 3 7.5% 0 0.0% 3 7.5%   
LWMI 
IWMI 0 0.0% 1 2.5% 1 2.5% 
  
Total 19 47.5% 21 52.5% 40 100.0%   
 
As the infarct size increases, there was increase in total count in our 
study which was statistically significant with a p value 0.002 
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                                MPV & PLATELET COUNT 
 
  
 PLATELET Total   
<2 LAKHS >2 LAKHS   
NO % NO % NO % r P 
value 
MPV 
<9.5 8 20.0% 14 35.0% 22 55.0%   
>9.5 17 42.5% 1 2.5% 18 45.0% 
-
0.597
* 
o.ooo 
Total 25 62.5% 15 37.5% 40 100.0%   
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CORRELATION BETWEEN MPV & PLATELET COUNT 
 
 
 
 In our study, as the mean platelet volume increases there was a 
decrease in platelet count which was statistically significant with a p value 
0.000 
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EF CLASS & MPV 
 MPV Total 
<9.5 >9.5 
EF CLASS 
20-40 
Count 1 6 7 
% within 
MPV 4.5% 33.3% 17.5% 
41-60 
Count 16 12 28 
% within 
MPV 72.7% 66.7% 70.0% 
ABOVE 
60 
Count 5 0 5 
% within 
MPV 22.7% 0.0% 12.5% 
Total 
Count 22 18 40 
% within 
MPV 100.0% 100.0% 100.0% 
 
Pearson chi-square test p value – 0.012 
 In our study, when there was high mean platelet volume, there was low 
ejection fraction which was statistically significant. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
EF 20 -40
5%
33%
EJECTION FRACTION & MPV
101 
EF 41- 60 EF >60
73%
22%
67%
0%
MPV <9.5 MPV >9.5
 
102 
 
INFARCT RELATED ARTERY AND MPV 
 MPV Total 
<9.5 >9.5 
IRA 
DISTAL LAD 
Count 3 0 3 
% within MPV 13.6% 0.0% 7.5% 
DISTAL RCA 
Count 4 0 4 
% within MPV 18.2% 0.0% 10.0% 
DISTALRCA 
Count 1 0 1 
% within MPV 4.5% 0.0% 2.5% 
LCX 
Count 3 0 3 
% within MPV 13.6% 0.0% 7.5% 
PROXIMAL LAD 
Count 8 0 8 
% within MPV 36.4% 0.0% 20.0% 
PROXIMAL LAD + PROXIMAL 
LCX  DISTAL RCA 
Count 0 1 1 
% within MPV 0.0% 5.6% 2.5% 
PROXIMAL LAD DISTAL LCX 
Count 0 2 2 
% within MPV 0.0% 11.1% 5.0% 
PROXIMAL LAD LCX 
Count 2 7 9 
% within MPV 9.1% 38.9% 22.5% 
PROXIMAL LAD MID LCX MID 
RCA 
Count 0 1 1 
% within MPV 0.0% 5.6% 2.5% 
PROXIMAL LAD PROXIMAL LCX  
DISTAL RCA 
Count 0 1 1 
% within MPV 0.0% 5.6% 2.5% 
PROXIMAL LAD RCA 
Count 0 1 1 
% within MPV 0.0% 5.6% 2.5% 
PROXIMAL RCA 
Count 1 1 2 
% within MPV 4.5% 5.6% 5.0% 
PROXIMAL RCA LCX 
Count 0 2 2 
% within MPV 0.0% 11.1% 5.0% 
PROXIMALRCA 
Count 0 2 2 
% within MPV 0.0% 11.1% 5.0% 
Total 
Count 22 18 40 
% within MPV 100.0% 100.0% 100.0% 
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 In our study, when there was high mean platelet volume, the most 
common site of lesion was in proximal LAD + proximal LCX followed by 
proximal LAD + distal LCX which was statistically significant with a p 
value 0.003. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
DISCUSSION 
  
104 
 
DISCUSSION 
 Our study was conducted in Institute of Internal Medicine and 
Department of cardiology, Madras Medical College and Rajiv Gandhi 
Government General Hospital, Chennai. 40 patients fulfilling the inclusion 
and exclusion criteria were included in our study. Following observations 
were made from our study. 
Age distribution: 
 Majority of cases were in the age group of 41-60 years with 27 
patients (67.5%). This was similar to the study of Mehmet Bilje et al. 
Sex distribution: 
 Out of 40 patients, 27 patients (67.5%) were males and 13 patients 
(32.5%) were females. Male to female ratio was 2:1 
Age group and platelet count: 
 The mean platelet count in patients <40 years was 1,30,000, in patients 
41-60 years it was 1,91,333 and in patiens >60 years it was 1,42,500. 
Mean platelet volume and Diabetes & Hypertension: 
 No significant correlation was observed in our study between mean 
platelet volume and Diabetes mellitus. 
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 Similarly there was no significant correlation between mean platelet 
volume and systemic hypertension. This was similar to the results from Bath 
et al (1996) 
Mean platelet volume and Smoking & alcoholism 
 There was no significant correlation observed between mean platelet 
volume and smoking & alcoholism in this study. 
Distribution of various types of MI: 
 Extensive anterior wall MI was the most common MI present in 14 
patients (35%), followed by anterior wall MI in 12 patients (30%) and 
inferior wall MI 7 patients (17.5%). 
Mean platelet volume and infarct size: 
There was a significant correlation between MPV >9.5 and the infarct 
size which was statistically significant (p value 0.000). As the MPV 
increases, the infarct size also increases. This observation was similar to the 
study of Morell et al. in which he correlated admission mean platelet volume 
to the infarct size assessed by cardiac MRI. 
Platelet count and infarct size: 
 There was a significant correlation between low platelet count (<1.5 
lakhs) and infarct size which was statistically significant. (p value – 0.001). 
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With decreasing platelet count, the infarct size increases. This was similar to 
the study of Mehmet Bilje et al. 
TIMI flow and Mean platelet volume: 
 There was a significant correlation between high mean platelet volume 
(>9.5) and low TIMI flow which was statistically significant (p value 0.000) 
which was similar to the study of Opolski G et al. 
Number of vessels and Mean platelet volume: 
As the number of infarcted vessels increase, there was a significant rise 
in mean platelet volume (>9.5) and this was statistically significant (p value – 
0.000). This was similar to the study of Murat Cayli et al. 
TIMI flow and type of MI: 
In this study there was a significant correlation between TIMI flow and 
type of MI which statistically significant (p value – 0.010). As the area of 
infarction increases there was low TIMI flow. 
Time window and Platelet count: 
As the time interval to treatment increases, more platelets will be 
consumed and platelet count will be low which statistically significant in 
study this with a p value 0.013. 
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Type of MI and total count: 
 In this study there was an increase in total count as the infarct size 
increases which was statistically significant (p value 0.002). This was similar 
to the observations made by James Scheuer et al. 
MPV and Platelet count: 
 As the mean platelet volume increases there was a decrease in platelet 
count in this study which was statistically significant (p value 0.000) 
Ejection fraction and MPV: 
 Significant correlation was observed in this study between MPV and 
ejection fraction. When there was high mean platelet volume, there was low 
ejection fraction which was statistically significant in our study (p value – 
0.012). This observation was similar to that of Celik S et al. 
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CONCLUSIONS 
 Admission mean platelet volume represents the reactivity of platelets – 
thrombus burden. 
 High admission mean platelet volume has significant impact on 
prognosis of myocardial infarction. 
 Admission mean platelet volume was not affected by diabetes mellitus, 
systemic hypertension, smoking, alcohol intake, age and sex. 
 Infarct size was directly proportional to admission mean platelet 
volume. 
 Successfulness of thrombolysis was inversely proportional to 
admission mean platelet volume. 
 Infarct related artery patency and TIMI flow were inversely 
proportional to admission mean platelet volume 
 Platelet count was inversely proportional to admission MPV. 
 Total count has correlated with infarct size. 
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IMPACT OF ADMISSION MEAN PLATELET VOLUME ON THE 
EFFICACY OF THROMBOLYSIS IN ST ELEVATION  
MYOCARDIAL INFARCTION 
 
PROFORMA 
  
Name:                                                                          Patient ID No: 
Age/sex:                                                                       Contact no: 
Occupation: 
DOA: 
DOD: 
COMPLAINTS: 
• Chestpain   
• Palpitation, 
• Syncope 
• Sweating 
• Shortness of breath 
• Orthopnea 
• Paroxysmal nocturnal dyspnea 
• Swelling of legs 
 
PAST HISTORY: 
• Diabetes mellitus/Stroke / TIA/Systemic hypertension/Coronary artery 
disease/Bronchial asthma 
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PERSONAL HISTORY: 
• Smoking  
• Alcohol intake 
 
 
GENERAL EXAMINATION: 
VITAL SIGNS: 
• Pulse                                              Respiratory Rate: 
• Blood pressure                               Temperature: 
 
SYSTEMIC EXAMINATION: 
• CVS: 
• RS: 
• P/A: 
• CNS: 
 
INVESTIGATIONS: 
 
 
 
 
 
 
 
 
 
 
 
 
Liver function test: 
TOTAL BILIRUBIN: 
DIRECT: 
SGOT: 
SGPT: 
ALP: 
T.PROTEIN: 
ALBUMIN: 
Renal function test- 
RBS: 
UREA: 
CREATININE: 
SODIUM: 
 
POTASSIUM: 
Complete blood count: 
WBC: 
DC: P-     L-     E-   
 
Hb: 
ESR: 
 PLT COUNT: 
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CORONARY ANGIOGRAM: 
  
 
 
 
 
 
 BEFORE THROMBOLYSIS AFTER THROMBOLYSIS 
MPV   
ECG   
ECHO   
ABBREVIATIONS 
STEMI - ST ELEVATION MYOCARDIAL INFARCTION 
IHD         -     ISCHEMIC HEART DISEASE 
MPV      -     MEAN PLTELET VOLUME 
IRA         -       INFARCT RELATED ARTERY 
TIMI  - THROMBOLYSIS IN MYOCARDIAL INFARCTION 
LBBB     -        LEFT BUNDLE BRANCH BLOCK 
PCI          -       PERCUTANEOUS CORONARY INTERVENTION 
CABG -       CORONARY ARTERY BYPASS GRAFT 
SVR   -        SYSTEMIC VASCULAR RESISTANCE 
LVEDP - LEFT VENTRICULAR END DIASTOLIC PRESSURE 
RAAS -  RENIN ANGIOTENSIN ACTIVATING SYSTEM 
ESR   -        ERYTHROCYTE SEDIMENTATION RATE 
CRP  - C-REACTIVE PROTEIN 
ESC   - EUROPEAN SOCIETY OF CARDIOLOGY 
ECG   - ELECTROCARDIOGRAM 
ASE   - AMERICAN SOCIETY OF ECHOCARDIOGRAPHY 
AHA  - AMERICAN HEART ASSOCIATION 
LDL   - LOW DENSITY LIPOPROTEIN 
VCAM - VASCULAR CELL ADHESION MOLECULE 
ICAM - INTRACELLULAR ADHESION MOLECULE 
MCP  - MONOCYTE CHEMOATTRACTANT PROTEIN 
M-CSF  - MACROPHAGE COLONY STIMULATING FACTOR 
vWF  - VON WILLEBRAND FACTOR 
PSGL  - P-SELECTIN GLYCOPROTEIN LIGAND 
NPH   - NEUTRAL PROTAMINE HAGEDORN 
MRI   - MAGNETIC RESONANCE IMAGING 
EF     - EJECTION FRACTION 
ATP  - ADENOSINE TRI PHOSPHATE  
ADP   - ADENOSINE DI PHOSPHATE 
EDTA - ETHYLENEDIAMINE TETRAACETIC ACID 
LAD  - LEFT ANTERIOR DESCENDING ARTERY 
RCA  - RIGHT CORONARY ARTERY 
LCX  - LEFT CIRCUMFLEX ARTERY 
SVD  - SINGLE VESSEL DISEASE 
DVD  - DOUBLE VESSEL DISEASE 
TVD  - TRIPLE VESSEL DISEASE 
  
  
 
 
 
TURNITIN PLAGIARISM SCREEN SHOT 
 
 
  
 
 PATIENT CONSENT FORM 
Study Detail : “IMPACT OF ADMISSION MEAN PLATELET VOLUME 
ON THE EFFICACY OF THROMBOLYSIS IN ST 
ELEVATION MYOCARDIAL INFARCTION” 
Study Centre : RajivGandhiGovernment GeneralHospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification Number :  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask question and all my questions and doubts have been 
answered to my complete satisfaction. ❏ 
b) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected. ❏ 
c) I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from 
the study I agree to this access. However, I understand that my identity will not 
be revealed in any information released to third parties or published, unless as 
required under the law. I agree not to restrict the use of any data or results that 
arise from this study. ❏ 
d) I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. ❏ 
e) I hereby consent to participate in this study. ❏ 
f) I hereby give permission to undergo detailed clinical examination and blood 
investigations as required. ❏ 
 
 
 
Signature/thumb impression 
 
 
Patient’s Name and Address:
Signature of Investigator 
 
 
Study Investigator’s Name: 
 
Dr RAGAVAN K  
INFORMATION SHEET 
 
TITLE:“IMPACT OF ADMISSION MEAN PLATELET VOLUME ON   THE 
EFFICACY OF THROMBOLYSIS IN ST ELEVATION MYOCARDIAL 
INFARCTION” 
 
NAME OF THE INVESTIGATOR: Dr.RAGAVAN K 
 
STUDY CENTRE: Rajiv Gandhi Government General Hospital, Chennai. 
 
NAME OF THE PARTICIPANT:   AGE:   SEX: 
 
PURPOSE OF THE STUDY: To know the impact of admission mean platelet volume on 
efficacy of thrombolysis in ST Elevation myocardial infarction. 
 
STUDY DESIGN: Observational study 
 
STUDY PROCEDURE: We are selecting certain patients if you are eligible after filling up 
the questionnaire, 3ml blood will be taken at the time of admission, ECG, blood biochemistry 
testing will be done. After thrombolysis coronary angiogram will be done. These tests and 
special studies do not affect your final report or management. 
 
POSSIBLE RISKS: No possible risks by means of this study. 
 
POSSIBLE BENEFITS: if we found there is impact of admission mean platelet volume on 
efficacy of thrombolysis in ST Elevation myocardial infarction, the success of thrombolysis 
can be predicted on admission itself. 
 
CONFIDENTIALITY OF THE INFORMATION OBTAINED FROM THE PATIENT: 
The privacy of the patients in the research will be maintained throughout the study. In the 
event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared. 
 
DECISION TO PARTICIPATE IN THE STUDY: Taking part in this study is voluntary. 
You are free to decide whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise entitled. 
 
RESULT OF THE STUDY: 
The results of the special study may be intimated to you at the end of the study period 
or during the study if anything is found abnormal which may aid in the management or 
treatment. 
 
Signature of Investigator Signature of Participant 
Date : 
Place : 
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